Small molecule progress for OncoTherapy as MELK inhibitor moves into clinic
This article was originally published in Scrip
Executive Summary
OncoTherapy Science has initiated a clinical program for its first small molecule drug candidate, beginning enrollment in a US Phase I trial for OTS167.